CD34 and acute myeloid leukemia: This was shown on sorted CD34+CD38− subpopulations from AML patients and healthy patients; ALDH1 inhibition was not toxic for healthy HSCs which retained, after treatment, their self-renewing and multi-lineage differentiation capacity in immunodeficient mice, xenografted with human leukemic cells.